Altamira Therapeutics (CYTO) Registration Filing summary

Company overview and business model

• Preclinical-stage biopharmaceutical company focused on peptide-based nanoparticle technologies for RNA delivery to extrahepatic tissues, with proprietary OligoPhore™ and Semaphore™ platforms.

• Two flagship siRNA programs (AM-401 for KRAS-driven cancer and AM-411 for rheumatoid arthritis) are in preclinical development; technology is also out-licensed to pharma and biotech partners.

• Recent strategic repositioning includes spinning off a majority stake in Altamira Medica AG (Bentrio® nasal spray) and plans to divest or partner other non-core programs.

• Recent collaborations and publications highlight advances in mRNA delivery and animal model efficacy, including partnerships with Univercells Group and research at Washington University.

Financial performance and metrics

• As of December 31, 2023, net tangible book value was $0.05 per share; pro forma as adjusted after the offering is estimated at $0.80 per share.

• Cash and cash equivalents as of December 31, 2023, were CHF 617,000; pro forma as adjusted post-offering is CHF 2,795,000.

• The company has incurred recurring losses and negative cash flows from operations since inception and expects continued losses due to R&D and public company costs.

• Total cash need for 2024 is projected at CHF 5.0–6.0 million, prior to any proceeds from this offering.

Use of proceeds and capital allocation

• Estimated net proceeds of $4.2 million (assuming full sale and exercise of Pre-Funded Warrants, no exercise of Common or Placement Agent Warrants) will be used for working capital and general corporate purposes.

• Management has broad discretion over the use of proceeds, which may be allocated to purposes not specified in the prospectus.

• Pending use, proceeds will be invested in short-term, investment-grade, interest-bearing instruments and U.S. government securities.